Tagged: cancer Toggle Comment Threads | Keyboard Shortcuts

  • NoCamels Team 1:39 pm on September 18, 2013 Permalink | Reply
    Tags: cancer, , , ,   

    CureTech Raises $3.8M 

    CureTech Raises $3.8MSeptember 18, 2013 | Israeli biotech startup CureTech, which develops innovative ways to treat cancer, has raised $3.8 million. The finances were raised in a rights issue to majority shareholder Clal.

  • NoCamels Team 3:41 pm on July 22, 2013 Permalink | Reply
    Tags: cancer, , , , , non-radioactive   

    Hadassah Ein-Kerem Researcher Receives €1.65 Grant From EU 

    Hadassah Ein-Kerem Researcher Receives €1.65 Grant From EUThe European Union has granted an Israeli researcher €1.65 million to continue her study into non-radioactive detection method of cancer and other conditions. Doctor Rahel Katz-Brill of Hadassah Ein-Kerem Medical Center in Jerusalem is the recipient of said grant and will use the grant to conduct pre-clinical trials of the substance.

  • NoCamels Team 5:03 pm on July 15, 2013 Permalink | Reply
    Tags: cancer, , tuberculosis, , vaxil, yorkville advisors   

    Cancer Vaccine Developer Vaxil Receives $3M Investment 

    Cancer Vaccine Developer Vaxil Receives $3M InvestmentIsraeli company Vaxil Biotherapeutics, which is developing vaccines for cancer and tuberculosis, has received a $3 million investment. The investment was made by Yorkville Advisors, which will transfer the funds over the next five years.

    Vaxil was founded in late 2006 and is headquartered at the Weizmann Science Park.

  • NoCamels Team 5:41 pm on April 9, 2013 Permalink | Reply
    Tags: aacr, alexander levitzki, , cancer, huji,   

    Israeli Professor Wins AACR Award For Outstanding Cancer Research 

    Israeli Professor Wins AACR Award For Outstanding Cancer ResearchThe American Association for Cancer Research (AACR) has chosen Professor Alexander Levitzki of the Hebrew University of Jerusalem as the winner of its 2013 Award for Outstanding Achievement in Chemistry in Cancer Research. The AACR said that Levitzki was chosen for the honor in recognition of his contributions to signal transduction therapy and his work on the development of tyrosine kinase inhibitors as effective agents against cancer.

  • NoCamels Team 11:51 am on October 23, 2012 Permalink | Reply
    Tags: , cancer, , sysmex   

    Japanese Giant Sysmex Intends On Buying Israeli Dune Medical Devices 

    Japanese Giant Sysmex Intend On Buying Israeli Dune Medical DevicesSysmex, a Japanese medical company worth $4.7 billion, is interested in buying Israeli company Dune Medical Devices, which develops systems for rapid examination of breast tumors. According to financial magazine Calcalist, the Japanese company has offered to buy the Israeli company for $200 million.

  • NoCamels Team 8:13 am on September 6, 2012 Permalink | Reply
    Tags: cancer, , ,   

    BiolineRX To Develop Clal Biotech’s Leukemia Drug 

    BiolineRX Will Develop Clal Biotech’s Leukemia Drug Israeli drug companies Clal Biotech Industries and BiolineRX sign an agreement for developing and commercializing Clal’s BL-8040, a drug designed for treating acute leukemia and other types of blood cancer. The American FDA has approved the companies’ investigational new drug application.

  • NoCamels Team 10:18 am on June 28, 2012 Permalink | Reply
    Tags: cancer, , Membrane, ,   

    ‘Compugen’: Positive Results For Cancer Treatment Protein 

    Compugen - News Flash - IsraelCompugen announced positive results for its trial of CGEN-15022, a membrane protein that was discovered by the company, as a treatment of multiple cancers such as liver, colorectal, lung and ovarian cancers. According to the company, the results indicate the potential of the protein as a compelling drug target for treatment of these cancers through monoclonal antibody (mAb) therapy. Compugen is a product discovery company focused on therapeutic proteins and monoclonal antibodies, based in Tel Aviv, Israel.

  • NoCamels Team 7:53 am on June 4, 2012 Permalink | Reply
    Tags: cancer, , Rituxan, Roche, , Treanda, ,   

    ‘Teva’: Positive Results For Lymphoma Treatment Trial 

    Teva - News Flash - IsraelTeva Pharmaceutical Industries announced positive results for its Treanda drug trial, for the treatment of lymphoma. During the trial, Treanda was given to patients with slow-growing lymphoma (non-Hodgkin lymphoma), in combination with Roche’s Rituxan. Results showed that patients treated with the combined drugs lived three years longer with no progression of their tumors, compared to those taking chemotherapy with Rituxan.

  • NoCamels Team 8:33 am on May 24, 2012 Permalink | Reply
    Tags: cancer, , monoclonal antibodies, ,   

    ‘IMMUNE Pharmaceuticals’ Partners With Weizmann Institute 

    IMMUNE - News Flash - IsraelIMMUNE Pharmaceuticals, a developer of monoclonal antibodies, and Yeda, the technology transfer company of the Weizmann Institute of Science, announced a broad collaboration to develop antibody therapeutics focusing on the development of new cancer treatments. IMMUNE Pharmaceuticals, an Israel and US based biopharmaceutical company, focuses on the development of next generation monoclonal antibodies addressing the treatment of cancer and inflammatory diseases.


  • NoCamels Team 10:36 am on April 1, 2012 Permalink | Reply
    Tags: biomarcare, cancer, , ,   

    BioMarCare Receives $1M Strategic Investment From Micromedic 

    Hadasit Bio-Holdings Ltd. a publicly traded portfolio of biotech companies, all based on intellectual property developed and owned by Hadassah University Hospital, Israel’s foremost medical research center, today announced that one of its portfolio company’s, BioMarCare, which does cancer diagnostics, received a $1 million strategic investment from Micromedic Ltd. with an option to invest an additional $1 million.

Compose new post
Next post/Next comment
Previous post/Previous comment
Show/Hide comments
Go to top
Go to login
Show/Hide help
shift + esc